MCID: DNG003
MIFTS: 60

Dengue Disease

Categories: Rare diseases, Infectious diseases

Aliases & Classifications for Dengue Disease

MalaCards integrated aliases for Dengue Disease:

Name: Dengue Disease 38 12 14
Dengue Fever 12 50 3 69
Dengue 52 41 42
Dengue Shock Syndrome 50 69
Df 50 3
Philippine Hemorrhagic Fever 50
Singapore Hemorrhagic Fever 50
Dengue Hemorrhagic Fever 50
Dengue Virus Infection 50
Thai Hemorrhagic Fever 50
Hemorrhagic Dengue 50
Classical Dengue 12
Breakbone Fever 12
Classic Dengue 12
Severe Dengue 69

Classifications:



Summaries for Dengue Disease

NIH Rare Diseases : 50 the following summary is from orphanet, a european reference portal for information on rare diseases and orphan drugs.orpha number: 99828disease definitiondengue fever (df), caused by dengue virus, is an arboviral disease characterized by an initial non-specific febrile illness that can sometimes progress to more severe forms manifesting capillary leakage and hemorrhage (dengue hemorrhagic fever, or dhf) and shock (dengue shock syndrome, or dss).epidemiologydf is found in the tropics worldwide, especially in southeast asia, the pacific region, and the americas, with 40% of the global population at risk. an estimated 50 to 100 million cases of df, 500,000 hospitalizations, and 20,000 deaths occur yearly worldwide.clinical descriptionthe vast majority of dengue virus infections result in df, which is characterized by sudden onset of fever, malaise, headache (classically retro-orbital), and myalgia/arthralgia, often followed soon after by a petechial rash, which may be pruritic. in most cases, symptoms will resolve within 7 days without further complications. however, in a small minority of patients, a brief period of deffervescence is followed by worsening abdominal symptoms (pain, nausea, vomiting, diarrhea), thrombocytopenia, hemorrhage (dhf: epistaxis, bleeding gums, gastrointestinal bleeding) and a capillary leak syndrome (dss: hemoconcentration, hypoalbuminemia, pleural effusion, shock). dhf/dss are seen most often in children under the age of 15 years. risk is greater with secondary heterologous infection by one of the four dengue virus serotypes, but severe disease may be seen with first infections.etiologyover 25 different viruses cause viral hemorrhagic fever. dengue virus belongs to the flaviviridae family, genus flavivirus. four distinct serotypes, with significant strain variation, are recognized. dengue viruses are maintained in humans and transmitted between them by the bite of infected mosquitoes, most commonly aedes aegypti but also aedes albopictus). person-to-person transmission has not been reported.diagnostic methodscommon diagnostic modalities include serologic testing by enzyme linked immunosorbent assay (elisa) and reverse transcriptionpolymerase chain reaction (rt-pcr). virus isolation may also be performed in specialized laboratories. the viremic phase of df/dhf is usually brief (first 3-5 days of illness), after which time detection of anti-dengue igm antibodies, which appear as early as 2-4 days after disease onset, is the mainstay. numerous commercial elisa assays are available with varying degrees of sensitivity and specificity.differential diagnosisdf is difficult to distinguish from a host of other febrile illnesses such as malaria and typhoid fever (see these terms), especially early in the course of disease before the rash appears. for dhf/dss, other viral hemorrhagic fevers, leptospirosis, rickettsial infection (see these terms) and meningococcemia need to be excluded.management and treatmentas there is presently no antiviral drug available for df/dhf, treatment is supportive, following the guidelines for treatment of severe septicemia. insecticide-treated bed nets, room screens and elimination of larval development sites should be used in open-air settings to prevent further transmission.prognosiscase-fatality rates for df are less than 1% but may rise to as high as 40% in dhf/dss, largely dependent upon whether access to advanced medical care exists. children and persons with underlying chronic diseases such as diabetes, heart disease, and asthma are at increased risk. the most severe phase of disease usually lasts only a few days and survivors generally have no lasting sequelae.visit the orphanet disease page for more resources. last updated: 12/1/2012

MalaCards based summary : Dengue Disease, also known as dengue fever, is related to dengue fever, protection against and dengue hemorrhagic fever, and has symptoms including diarrhea, headache and hepatomegaly. An important gene associated with Dengue Disease is CD209 (CD209 Molecule), and among its related pathways/superpathways are Innate Immune System and Class I MHC mediated antigen processing and presentation. The drugs Histamine and Ketotifen have been mentioned in the context of this disorder. Affiliated tissues include skin, testes and bone, and related phenotypes are hematopoietic system and immune system

MedlinePlus : 41 dengue is an infection caused by a virus. you can get it if an infected mosquito bites you. dengue does not spread from person to person. it is common in warm, wet areas of the world. outbreaks occur in the rainy season. dengue is rare in the united states. symptoms include a high fever, headaches, joint and muscle pain, vomiting, and a rash. in some cases, dengue turns into dengue hemorrhagic fever, which causes bleeding from your nose, gums, or under your skin. it can also become dengue shock syndrome, which causes massive bleeding and shock. these forms of dengue are life-threatening. there is no specific treatment. most people with dengue recover within 2 weeks. until then, drinking lots of fluids, resting and taking non-aspirin fever-reducing medicines might help. people with the more severe forms of dengue usually need to go to the hospital and get fluids. to lower your risk when traveling to areas where dengue is found wear insect repellent with deet wear clothes that cover your arms, legs and feet close unscreened doors and windows nih: national institute of allergy and infectious diseases

CDC : 3 With more than one-third of the world’s population living in areas at risk for infection, dengue virus is a leading cause of illness and death in the tropics and subtropics. As many as 400 million people are infected yearly. Dengue is caused by any one of four related viruses transmitted by mosquitoes. There are not yet any vaccines to prevent infection with dengue virus and the most effective protective measures are those that avoid mosquito bites. When infected, early recognition and prompt supportive treatment can substantially lower the risk of medical complications and death.

Disease Ontology : 12 A viral infectious disease that results_in infection, has material basis in Dengue virus [NCBITaxon:12637] with four serotypes (Dengue virus 1, 2, 3 and 4), which are transmitted_by Aedes mosquito bite. The infection has symptom fever, has symptom severe headache, has symptom severe pain behind the eyes, has symptom joint pain, has symptom muscle and bone pain, has symptom rash, and has symptom mild bleeding.

Related Diseases for Dengue Disease

Diseases related to Dengue Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 51)
id Related Disease Score Top Affiliating Genes
1 dengue fever, protection against 12.3
2 dengue hemorrhagic fever 10.8
3 dengue shock syndrome 10.8
4 asymptomatic dengue 10.8
5 lymphomatous thyroiditis 10.7 ICAM1 VCAM1
6 imperforate oropharynx-costo vetebral anomalies 10.7 CD40LG MBL2
7 hodgkin's lymphoma, nodular sclerosis 10.7 CD40LG ICAM1
8 heart lymphoma 10.7 ICAM1 VCAM1
9 marginal corneal ulcer 10.6 ICAM1 VCAM1
10 cystic adventitial disease 10.6 IL11 THPO
11 cerebral neuroblastoma 10.6 CD209 CD40LG
12 trichostrongyloidiasis 10.6 CD40LG PIK3C2A
13 acute kidney tubular necrosis 10.6 CD40LG PIK3C2A
14 gonococcal synovitis 10.6 CD40LG MBL2
15 indian tick typhus 10.5 CCL5 CD40LG
16 hemorrhagic fever with renal syndrome 10.5 CD40LG PIK3C2A
17 erysipelas 10.5 CD40LG RAF1
18 mental depression 10.5 CD40LG THPO
19 dislocation of ear ossicle 10.5 CD40LG ICAM1 VCAM1
20 vaginal mullerian papilloma 10.5 CD209 CD40LG
21 dysphagia 10.5 CCL5 ICAM1 VCAM1
22 orbital melanoma 10.5 CCL5 ICAM1 VCAM1
23 ragweed sensitivity 10.4 CCL5 ICAM1 VCAM1
24 angiokeratoma 10.4 ICAM1 VCAM1
25 pulmonary tuberculosis 10.4 CCL5 CD209 CD40LG
26 hyperpigmentation of eyelid 10.4 CCL5 ICAM1 VCAM1
27 chickenpox 10.4 CD40LG ICAM1 VCAM1
28 chronic inflammatory demyelinating polyneuritis 10.4 CD40LG THPO
29 iida kannari syndrome 10.4 CCL5 CD40LG THPO
30 ocular albinism, x-linked 10.4 PTPN11 RAF1
31 acute chest syndrome 10.4 CCL5 CD40LG ICAM1
32 histoplasmosis pericarditis 10.4 ICAM1 PIK3C2A VCAM1
33 inferolateral myocardial infarct 10.4 ICAM1 VCAM1
34 malignant epithelial mesothelioma 10.4 CCL5 ICAM1 VCAM1
35 causalgia 10.3 CCL5 CD40LG ICAM1
36 granuloma annulare 10.3 CD40LG ICAM1 VCAM1
37 carotid artery dissection 10.3 CCL5 CD209 CD40LG
38 cannabis abuse 10.3 CCL5 ICAM1
39 japanese encephalitis 10.3 CD40LG RAF1
40 craniopharyngioma 10.3 FCGR1A ICAM1 VCAM1
41 advanced sleep phase syndrome, familial, 1 10.2 CCL5 CD40LG ICAM1 VCAM1
42 trigonocephaly with short stature and developmental delay 10.1 PTPN11 VCAM1
43 adenoid squamous cell carcinoma 10.1 CCL5 CD40LG MBL2 PIK3C2A
44 moved to 244450 10.1 ICAM1 VCAM1
45 rheumatoid arthritis 9.9 CCL5 CD40LG ICAM1 IL11 VCAM1
46 asthma 9.8 CCL5 CD40LG ICAM1 IL11 VCAM1
47 endotheliitis 9.6
48 thrombocytopenia 9.5
49 hemorrhagic fever 9.5
50 systemic lupus erythematosus 9.1 CCL5 CD40LG FCGR1A ICAM1 MBL2 SULT1A3

Graphical network of the top 20 diseases related to Dengue Disease:



Diseases related to Dengue Disease

Symptoms & Phenotypes for Dengue Disease

Human phenotypes related to Dengue Disease:

32 (show all 22)
id Description HPO Frequency HPO Source Accession
1 diarrhea 32 occasional (7.5%) HP:0002014
2 headache 32 hallmark (90%) HP:0002315
3 hepatomegaly 32 occasional (7.5%) HP:0002240
4 lethargy 32 occasional (7.5%) HP:0001254
5 thrombocytopenia 32 occasional (7.5%) HP:0001873
6 leukopenia 32 occasional (7.5%) HP:0001882
7 epistaxis 32 occasional (7.5%) HP:0000421
8 petechiae 32 occasional (7.5%) HP:0000967
9 fever 32 hallmark (90%) HP:0001945
10 abdominal pain 32 frequent (33%) HP:0002027
11 hypoproteinemia 32 occasional (7.5%) HP:0003075
12 ascites 32 occasional (7.5%) HP:0001541
13 pruritus 32 frequent (33%) HP:0000989
14 hypotension 32 occasional (7.5%) HP:0002615
15 cerebral hemorrhage 32 occasional (7.5%) HP:0001342
16 skin rash 32 frequent (33%) HP:0000988
17 arthralgia 32 frequent (33%) HP:0002829
18 gingival bleeding 32 occasional (7.5%) HP:0000225
19 gastrointestinal hemorrhage 32 occasional (7.5%) HP:0002239
20 nausea and vomiting 32 occasional (7.5%) HP:0002017
21 bruising susceptibility 32 occasional (7.5%) HP:0000978
22 cardiorespiratory arrest 32 occasional (7.5%) HP:0006543

UMLS symptoms related to Dengue Disease:


fever, pruritus

MGI Mouse Phenotypes related to Dengue Disease:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.65 PTPN11 RAF1 THPO VCAM1 CCL5 CD40LG
2 immune system MP:0005387 9.32 CCL5 CD40LG FCGR1A ICAM1 MBL2 PIK3C2A

Drugs & Therapeutics for Dengue Disease

Drugs for Dengue Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 47)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Histamine Approved, Investigational Phase 4 75614-87-8, 51-45-6 774
2
Ketotifen Approved Phase 4 34580-14-8, 34580-13-7 3827
3 Anti-Allergic Agents Phase 4
4 Antipruritics Phase 4
5 Dermatologic Agents Phase 4
6 Histamine Antagonists Phase 4
7 Histamine H1 Antagonists Phase 4
8
Histamine Phosphate Phase 4 51-74-1 65513
9 Neurotransmitter Agents Phase 4
10 DEET Phase 3
11 Insect Repellents Phase 3
12 Protective Agents Phase 3
13 Vaccines Phase 3,Phase 2,Phase 1
14 Pharmaceutical Solutions Phase 3,Phase 1,Phase 2
15
Hydrocortisone Approved, Vet_approved Phase 2 50-23-7 5754 657311
16
Ribavirin Approved Phase 2 36791-04-5 37542
17
chloroquine Approved, Vet_approved Phase 1, Phase 2 54-05-7 2719
18
Neomycin Approved, Vet_approved Phase 1, Phase 2 1404-04-2 8378
19 Anti-Infective Agents Phase 2,Phase 1
20 Antimetabolites Phase 2
21 Antiviral Agents Phase 2
22 Cortisol succinate Phase 2
23 Hydrocortisone 17-butyrate 21-propionate Phase 2
24 Hydrocortisone acetate Phase 2
25 Analgesics Phase 1, Phase 2
26 Analgesics, Non-Narcotic Phase 1, Phase 2
27 Anthelmintics Phase 1, Phase 2
28 Anti-Inflammatory Agents Phase 1, Phase 2
29 Anti-Inflammatory Agents, Non-Steroidal Phase 1, Phase 2
30 Antimalarials Phase 1, Phase 2
31 Antiparasitic Agents Phase 1, Phase 2
32 Antiprotozoal Agents Phase 1, Phase 2
33 Antirheumatic Agents Phase 1, Phase 2
34 Chloroquine diphosphate Phase 1, Phase 2 50-63-5
35 Peripheral Nervous System Agents Phase 1, Phase 2
36 Heptavalent Pneumococcal Conjugate Vaccine Phase 2
37 Coagulants Phase 2
38 Hemostatics Phase 2
39 Antibodies Phase 1, Phase 2
40 Immunoglobulins Phase 1, Phase 2
41
Aluminum hydroxide Approved Phase 1 21645-51-2
42
Aluminum sulfate Approved Phase 1 10043-01-3
43 Adjuvants, Immunologic Phase 1
44 Antacids Phase 1
45 Anti-Ulcer Agents Phase 1
46 Gastrointestinal Agents Phase 1
47
Permethrin Approved, Investigational 52645-53-1 40326

Interventional clinical trials:

(show top 50) (show all 83)

id Name Status NCT ID Phase Drugs
1 Ketotifen as a Treatment for Vascular Leakage During Dengue Fever Recruiting NCT02673840 Phase 4 Ketotifen;Placebo
2 Clinical Evaluation of Insect Repellent and Insecticide Treated Nets in Lao PDR Unknown status NCT00938379 Phase 3 20% deet insect repellent;placebo control
3 Phase III Trial to Evaluate Efficacy and Safety of a Tetravalent Dengue Vaccine Recruiting NCT02406729 Phase 3
4 Study of a Novel Tetravalent Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America Active, not recruiting NCT01374516 Phase 3
5 Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Gardasil® Active, not recruiting NCT02993757 Phase 3
6 Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Cervarix® Active, not recruiting NCT02979535 Phase 3
7 Chinese and Western Medicine Treatment of Fever Associated With Bleeding Symptoms Unknown status NCT01973855 Phase 2 Western Medicine;TCM and Western Medicine
8 The Effect of Chloroquine in the Treatment of Patients With Dengue Unknown status NCT00849602 Phase 1, Phase 2 Placebo;Chloroquine
9 Safety and Immunogenicity of Formulations of Dengue Vaccines in Healthy Flavivirus-Naïve Adults Completed NCT00740155 Phase 2
10 Efficacy and Safety of Dengue Vaccine in Healthy Children Completed NCT00842530 Phase 2
11 Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Subjects Completed NCT00875524 Phase 2
12 Study of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Subjects in Singapore Completed NCT00880893 Phase 2
13 Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Peruvian Children Aged 2 to 11 Years Completed NCT00788151 Phase 2
14 Activated Recombinant Human Factor VII in Patients With Dengue Haemorrhagic Fever Completed NCT01601613 Phase 2 activated recombinant human factor VII;placebo
15 A Phase I/II Trial of Tetravalent Live Attenuated Dengue Vaccine in Flavivirus Antibody Naive Infants Completed NCT00322049 Phase 1, Phase 2
16 The Role of Pre-existing Cross-reactive Antibodies in Determining the Efficacy of Vaccination in Humans Completed NCT01943305 Phase 2
17 Evaluating the Safety of and Immune Response to a Dengue Vaccine (TV003) in Healthy Adults, Adolescents, and Children in Thailand Recruiting NCT02332733 Phase 2
18 Study of Varying Injection Schedules of TDENV-PIV Vaccine With AS03B Adjuvant and Placebo in Healthy US Adults Recruiting NCT02421367 Phase 1, Phase 2
19 Safety and Immunogenicity of the Dengue Virus Vaccine TV005 (TetraVax-DV TV005) in Healthy Adults, Adolescents, and Children in Dhaka, Bangladesh Active, not recruiting NCT02678455 Phase 2
20 Celgosivir or Modipafant as Treatment for Adult Participants With Uncomplicated Dengue Fever in Singapore Not yet recruiting NCT02569827 Phase 1, Phase 2 Celgosivir;Modipafant 50mg;Placebo;Modipafant 100mg
21 Evaluation of the Safety and the Ability of a DNA Vaccine to Protect Against Dengue Disease Completed NCT01502358 Phase 1
22 Safety Study of a Vaccine (DENV-1 PIV) to Prevent Dengue Disease Completed NCT01502735 Phase 1
23 Tetravalent Chimeric Dengue Vaccine Trial Completed NCT01110551 Phase 1 Placebo (SC);Placebo (ID)
24 Evaluating the Safety and Effectiveness of a Dengue Virus Vaccine in Healthy Adults Completed NCT02021968 Phase 1
25 Safety and Immune Response to an Investigational Dengue Type 2 Vaccine Completed NCT01073306 Phase 1
26 Evaluating the Safety and Immune Response to Two Doses of a Dengue Virus Vaccine Administered 12 Months Apart Completed NCT01782300 Phase 1
27 Evaluation of the Safety and Immune Response to an Investigational Dengue Type 1 Vaccine Completed NCT01084291 Phase 1
28 Safety of and Immune Response to DEN4 Vaccine Component Candidate for Dengue Virus Completed NCT00919178 Phase 1
29 Evaluating the Safety and Immune Response to Two Admixtures of a Tetravalent Dengue Virus Vaccine Completed NCT01436422 Phase 1
30 Evaluation of the Safety and Immune Response of Five Admixtures of a Tetravalent Dengue Virus Vaccine Completed NCT01072786 Phase 1
31 Evaluating the Safety and Immune Response to Two Admixtures of a Tetravalent Dengue Virus Vaccine Completed NCT01506570 Phase 1
32 Safety of and Immune Response to a West Nile Virus Vaccine (WN/DEN4-3'delta30) in Healthy Adults Completed NCT00094718 Phase 1
33 Evaluating the Safety and Protective Efficacy of a Single Dose of a Trivalent Live Attenuated Dengue Vaccine to Protect Against Infection With DENV-2 Completed NCT02433652 Phase 1
34 Safety of and Immune Response to a West Nile Virus Vaccine (WN/DEN4delta30) in Healthy Adults Completed NCT00537147 Phase 1
35 Safety of and Immune Response to Two Different Dengue Virus Vaccines in Individuals Previously Immunized Against Dengue Virus Completed NCT00458120 Phase 1
36 Evaluating the Safety, Tolerability, and Immunogenicity of a Tetravalent Dengue Vaccine (V180) in Healthy Adults Who Previously Received a Live-Attenuated Tetravalent Vaccine (TV003 or TV005) Completed NCT02450838 Phase 1
37 Safety of and Immune Response to a Dengue Virus Vaccine (rDEN1delta30) in Healthy Adults Completed NCT00089908 Phase 1
38 Safety of and Immune Response to a Dengue Virus Vaccine (rDEN2/4delta30[ME]) in Healthy Adults Completed NCT00094705 Phase 1
39 Safety of and Immune Response to a Dengue Virus Vaccine (rDEN4delta30-200,201) in Healthy Adults Completed NCT00270699 Phase 1
40 Evaluation of the Safety and Immunogenicity of rDEN3Δ30, a Live Attenuated Monovalent Dengue Virus Vaccine Completed NCT02684383 Phase 1
41 Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3delta30/31‐7164) in Healthy Adults Completed NCT00831012 Phase 1
42 Safety of and Immune Response of a 2-dose Regimen of rDEN1delta30 Dengue Virus Vaccine Completed NCT00473135 Phase 1
43 Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3/4delta30[ME]) in Healthy Adults Completed NCT00375726 Phase 1
44 Safety of and Immune Response to a Dengue Virus Vaccine (rDEN4delta30-4995) in Healthy Adults Completed NCT00322946 Phase 1
45 Evaluation of the Safety and Efficacy of a Single Dose of a Dengue Vaccine (TV005) in Healthy Adults Completed NCT02317900 Phase 1
46 Evaluating the Safety and Immune Response to a Dengue Virus Vaccine in Healthy Adults Completed NCT01931176 Phase 1
47 Safety of and Immune Response to a Dengue Virus Vaccine (rDEN3-3'Ddelta30) in Healthy Adults Completed NCT00712803 Phase 1
48 Safety and Immune Response to Two Doses of rDEN2/4delta30 Dengue Vaccine Completed NCT00920517 Phase 1
49 Safety of and Immune Response to a Tick-Borne Encephalitis Vaccine (LGT(TP21)/DEN4) in Healthy Adults Completed NCT00118924 Phase 1
50 Evaluating the Safety and Immunogenicity of a Live Attenuated West Nile Virus Vaccine for West Nile Encephalitis in Adults 50 to 65 Years of Age Completed NCT02186626 Phase 1

Search NIH Clinical Center for Dengue Disease

Cochrane evidence based reviews: dengue

Genetic Tests for Dengue Disease

Anatomical Context for Dengue Disease

MalaCards organs/tissues related to Dengue Disease:

39
Skin, Testes, Bone, Heart, Eye, Thyroid, T Cells

Publications for Dengue Disease

Articles related to Dengue Disease:

(show top 50) (show all 92)
id Title Authors Year
1
Bayesian dynamic modeling of time series of dengue disease case counts. ( 28671941 )
2017
2
Epidemiological Characteristics of Dengue Disease in Latin America and in the Caribbean: A Systematic Review of the Literature. ( 28392806 )
2017
3
Transcriptional Profiling Confirms the Therapeutic Effects of Mast Cell Stabilization in a Dengue Disease Model. ( 28659489 )
2017
4
Effect of Rainfall for the Dynamical Transmission Model of the Dengue Disease in Thailand. ( 28928793 )
2017
5
Relative risk estimation of dengue disease at small spatial scale. ( 28810908 )
2017
6
Trends of Dengue Disease Epidemiology. ( 28579763 )
2017
7
Mannose-binding lectin gene (MBL2) polymorphisms related to the mannose-binding lectin low levels are associated to dengue disease severity. ( 27180198 )
2016
8
High prevalence of clinically unsuspected dengue disease among children in Ribeirao Preto City, Brazil. ( 27004990 )
2016
9
Seasonal Distribution and Climatic Correlates of Dengue Disease in Dhaka, Bangladesh. ( 27114293 )
2016
10
Tetravalent Dengue Vaccine: A Review in the Prevention of Dengue Disease. ( 27506852 )
2016
11
Relative Contribution of Dengue IgG Antibodies Acquired during Gestation or Breastfeeding in Mediating Dengue Disease Enhancement and Protection in Type I Interferon Receptor-Deficient Mice. ( 27341339 )
2016
12
Clinical and laboratory signs associated to severe dengue disease in hospitalized children. ( 27112034 )
2016
13
Symptomatic Dengue Disease in Five Southeast Asian Countries: Epidemiological Evidence from a Dengue Vaccine Trial. ( 27532617 )
2016
14
Early diagnosis of dengue disease severity in a resource-limited Asian country. ( 27670906 )
2016
15
Dengue Disease Modelling and Forecasting: Utility and Limitations. ( 27292001 )
2016
16
Antibody-enhanced dengue disease generates a marked CNS inflammatory response in the black-tufted marmoset Callithrix penicillata. ( 26303046 )
2015
17
Antibodies against immature virions are not a discriminating factor for dengue disease severity. ( 25760350 )
2015
18
Epidemiological trends of dengue disease in Colombia (2000-2011): a systematic review. ( 25790245 )
2015
19
Influence of antibodies and T cells on dengue disease outcome: insights from interferon receptor-deficient mouse models. ( 26001278 )
2015
20
Biomarkers of severe dengue disease - a review. ( 26462910 )
2015
21
Evolution of dengue disease and entomological monitoring in Santa Cruz, Bolivia 2002 - 2008. ( 25706631 )
2015
22
Epidemiological and demographic characteristics of dengue disease at a tertiary care centre in Saurashtra region during the year 2013. ( 26714509 )
2015
23
Dengue disease outbreak definitions are implicitly variable. ( 25979287 )
2015
24
Dengue Disease Risk Mental Models in the City of Dhaka, Bangladesh: Juxtapositions and Gaps Between the Public and Experts. ( 26387980 )
2015
25
Protection against dengue disease by synthetic nucleic acid antibody prophylaxis/immunotherapy. ( 26220099 )
2015
26
Dengue disease outbreak detection. ( 25160360 )
2014
27
Dengue disease surveillance: an updated systematic literature review. ( 24889501 )
2014
28
NK Cells during Dengue Disease and Their Recognition of Dengue Virus-Infected cells. ( 24829565 )
2014
29
Association between proinflammatory cytokines and lipid peroxidation in patients with severe dengue disease around defervescence. ( 24216294 )
2014
30
Reviewing the literature for epidemiological trends of dengue disease: introduction to a series of seven national systematic literature reviews. ( 25375830 )
2014
31
Epidemiological trends of dengue disease in Thailand (2000-2011): a systematic literature review. ( 25375766 )
2014
32
Epidemiology of Dengue Disease in the Philippines (2000-2011): A Systematic Literature Review. ( 25375119 )
2014
33
Predictive symptoms and signs of severe dengue disease for patients with dengue fever: a meta-analysis. ( 25097856 )
2014
34
Evaluation of the WHO classification of dengue disease severity during an epidemic in 2011 in the state of CearA!, Brazil. ( 24626308 )
2014
35
First experimental in vivo model of enhanced dengue disease severity through maternally acquired heterotypic dengue antibodies. ( 24699622 )
2014
36
Dengue disease surveillance: improving data for dengue control. ( 25375232 )
2014
37
CD8+ T cells prevent antigen-induced antibody-dependent enhancement of dengue disease in mice. ( 25217165 )
2014
38
Epidemiology of dengue disease in malaysia (2000-2012): a systematic literature review. ( 25375211 )
2014
39
Epidemiological trends of dengue disease in Mexico (2000-2011): a systematic literature search and analysis. ( 25375162 )
2014
40
Dogma in classifying dengue disease. ( 23926138 )
2013
41
Spatial distribution of dengue disease in municipality of MossorA^, Rio Grande do Norte, using the Geographic Information System. ( 24896274 )
2013
42
The battle between infection and host immune responses of dengue virus and its implication in dengue disease pathogenesis. ( 23476150 )
2013
43
Epidemiological trends of dengue disease in Brazil (2000-2010): a systematic literature search and analysis. ( 24386496 )
2013
44
Knowledge, attitude, and practice of dengue disease among healthcare professionals in southern Taiwan. ( 23332425 )
2013
45
Comment on: "Atypical presentations of dengue disease in the elderly visiting the ED" ( 24342867 )
2013
46
An optimal control problem arising from a dengue disease transmission model. ( 23274179 )
2013
47
Atypical presentations of dengue disease in the elderly visiting the ED. ( 23399333 )
2013
48
Assessing weather effects on dengue disease in malaysia. ( 24287855 )
2013
49
Can non-human primates serve as models for investigating dengue disease pathogenesis? ( 24130557 )
2013
50
Association of human immune response to Aedes aegypti salivary proteins with dengue disease severity. ( 21995849 )
2012

Variations for Dengue Disease

Expression for Dengue Disease

LifeMap Discovery
Genes differentially expressed in tissues of Dengue Disease patients vs. healthy controls: 35 (show top 50) (show all 93)
id Gene Description Tissue Up/Dn Fold Change (log2) P value
1 IFI27 interferon, alpha-inducible protein 27 Blood + 4.85 0.000
2 RRM2 ribonucleotide reductase M2 Blood + 4.48 0.000
3 CEP55 centrosomal protein 55kDa Blood + 4.33 0.000
4 BIRC5 baculoviral IAP repeat containing 5 Blood + 4.30 0.000
5 XIST X inactive specific transcript (non-protein coding) Blood - 4.25 0.009
6 CD38 CD38 molecule Blood + 4.23 0.000
7 DLGAP5 discs, large (Drosophila) homolog-associated protein 5 Blood + 4.10 0.000
8 BUB1 BUB1 mitotic checkpoint serine/threonine kinase Blood + 4.08 0.000
9 IGHM immunoglobulin heavy constant mu Blood + 4.04 0.000
10 MCM10 minichromosome maintenance 10 replication initiation factor Blood + 3.99 0.000
11 SHCBP1 SHC SH2-domain binding protein 1 Blood + 3.97 0.000
12 PBK PDZ binding kinase Blood + 3.97 0.000
13 TYMS thymidylate synthetase Blood + 3.96 0.000
14 PI3 peptidase inhibitor 3, skin-derived Blood - 3.93 0.000
15 CDCA2 cell division cycle associated 2 Blood + 3.91 0.000
16 SESN3 sestrin 3 Blood - 3.90 0.000
17 HMMR hyaluronan-mediated motility receptor (RHAMM) Blood + 3.83 0.000
18 MKI67 marker of proliferation Ki-67 Blood + 3.83 0.000
19 ZWINT ZW10 interacting kinetochore protein Blood + 3.83 0.000
20 DTL denticleless E3 ubiquitin protein ligase homolog (Drosophila) Blood + 3.80 0.000
21 CDK1 cyclin-dependent kinase 1 Blood + 3.78 0.000
22 NCAPG non-SMC condensin I complex, subunit G Blood + 3.76 0.000
23 CDT1 chromatin licensing and DNA replication factor 1 Blood + 3.76 0.000
24 SPC25 SPC25, NDC80 kinetochore complex component Blood + 3.75 0.000
25 CDC20 cell division cycle 20 Blood + 3.73 0.000
26 CNTNAP3 contactin associated protein-like 3 Blood - 3.72 0.000
27 TOP2A topoisomerase (DNA) II alpha Blood + 3.71 0.000
28 NOV nephroblastoma overexpressed Blood - 3.71 0.000
29 EIF1AY eukaryotic translation initiation factor 1A, Y-linked Blood + 3.69 0.015
30 CCNB2 cyclin B2 Blood + 3.62 0.000
31 CDKN3 cyclin-dependent kinase inhibitor 3 Blood + 3.62 0.000
32 KIAA0101 KIAA0101 Blood + 3.61 0.000
33 KIF2C kinesin family member 2C Blood + 3.60 0.000
34 TK1 thymidine kinase 1, soluble Blood + 3.59 0.000
35 RPS4Y1 ribosomal protein S4, Y-linked 1 Blood + 3.57 0.017
36 TTK TTK protein kinase Blood + 3.56 0.000
37 CDC6 cell division cycle 6 Blood + 3.56 0.000
38 CAV1 caveolin 1, caveolae protein, 22kDa Blood + 3.56 0.000
39 CENPA centromere protein A Blood + 3.54 0.000
40 CYAT1 immunoglobulin lambda light chain-like Blood + 3.52 0.000
41 ASPM abnormal spindle microtubule assembly Blood + 3.52 0.000
42 OR2W3 olfactory receptor, family 2, subfamily W, member 3 Blood - 3.51 0.000
43 UHRF1 ubiquitin-like with PHD and ring finger domains 1 Blood + 3.50 0.000
44 SELENBP1 selenium binding protein 1 Blood - 3.50 0.000
45 GINS2 GINS complex subunit 2 (Psf2 homolog) Blood + 3.49 0.000
46 MELK maternal embryonic leucine zipper kinase Blood + 3.47 0.000
47 BUB1B BUB1 mitotic checkpoint serine/threonine kinase B Blood + 3.47 0.000
48 CHEK1 checkpoint kinase 1 Blood + 3.46 0.000
49 CCNB1 cyclin B1 Blood + 3.45 0.000
50 KIF11 kinesin family member 11 Blood + 3.42 0.000
Search GEO for disease gene expression data for Dengue Disease.

Pathways for Dengue Disease

Pathways related to Dengue Disease according to GeneCards Suite gene sharing:

(show all 22)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.87 CCL5 CD209 CD40LG FCGR1A ICAM1 IL11
2
Show member pathways
13.25 CD209 CD40LG FCGR1A ICAM1 PTPN11 RAF1
3
Show member pathways
12.97 CCL5 CD40LG FCGR1A ICAM1 IL11 PTPN11
4
Show member pathways
12.35 FCGR1A ICAM1 PTPN11 VCAM1
5
Show member pathways
12.19 ICAM1 PTPN11 RAF1 VCAM1
6
Show member pathways
11.94 IL11 PTPN11 RAF1 THPO
7 11.9 IL11 THPO VCAM1
8
Show member pathways
11.86 CCL5 CD209 HCFC1 ICAM1 IVNS1ABP PTPN11
9 11.84 CD209 IL11 THPO
10 11.78 CCL5 ICAM1 VCAM1
11 11.75 CD40LG FCGR1A ICAM1 VCAM1
12 11.71 FCGR1A IL11 THPO
13 11.69 CD40LG ICAM1 VCAM1
14 11.64 CCL5 ICAM1 IL11
15 11.5 CD40LG ICAM1 VCAM1
16
Show member pathways
11.43 CD40LG ICAM1 VCAM1
17 11.36 FCGR1A ICAM1 MBL2
18 11.23 CD40LG ICAM1 VCAM1
19 11.1 ICAM1 PTPN11 RAF1 VCAM1
20 10.95 CD209 RAF1
21 10.9 ICAM1 IL11 PTPN11 RAF1
22 10.79 ICAM1 VCAM1

GO Terms for Dengue Disease

Cellular components related to Dengue Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.7 CCL5 CD40LG ICAM1 IL11 MBL2 THPO
2 cell surface GO:0009986 9.35 CD209 CD40LG ICAM1 MBL2 VCAM1
3 external side of plasma membrane GO:0009897 8.92 CD209 CD40LG ICAM1 VCAM1

Biological processes related to Dengue Disease according to GeneCards Suite gene sharing:

(show all 14)
id Name GO ID Score Top Affiliating Genes
1 viral process GO:0016032 9.72 CD209 HCFC1 ICAM1 IVNS1ABP VCAM1
2 cellular response to tumor necrosis factor GO:0071356 9.71 CCL5 ICAM1 VCAM1
3 platelet activation GO:0030168 9.7 CD40LG PTPN11 RAF1
4 regulation of immune response GO:0050776 9.67 CD40LG FCGR1A ICAM1 VCAM1
5 interferon-gamma-mediated signaling pathway GO:0060333 9.63 FCGR1A ICAM1 VCAM1
6 B cell differentiation GO:0030183 9.61 CD40LG IL11 VCAM1
7 positive regulation of T cell proliferation GO:0042102 9.58 CCL5 CD40LG VCAM1
8 regulation of protein complex assembly GO:0043254 9.51 HCFC1 PTPN11
9 neurotrophin TRK receptor signaling pathway GO:0048011 9.49 PTPN11 RAF1
10 negative regulation of hormone secretion GO:0046888 9.48 IL11 PTPN11
11 heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules GO:0007157 9.43 CD209 ICAM1 VCAM1
12 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.35 CCL5 ICAM1 PTPN11 RAF1 THPO
13 membrane to membrane docking GO:0022614 9.16 ICAM1 VCAM1
14 leukocyte cell-cell adhesion GO:0007159 9.02 CCL5 CD209 CD40LG ICAM1 VCAM1

Molecular functions related to Dengue Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 mannose binding GO:0005537 8.96 CD209 MBL2
2 cytokine activity GO:0005125 8.92 CCL5 CD40LG IL11 THPO

Sources for Dengue Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....